Zacks Research Issues Negative Estimate for Danaher Earnings

Danaher Co. (NYSE:DHR) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings estimates for shares of Danaher in a report issued on Wednesday, February 19th. Zacks Research analyst R. Department now expects that the conglomerate will post earnings per share of $1.62 for the quarter, down from their prior estimate of $2.00. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s Q4 2025 earnings at $2.36 EPS.

Several other analysts have also commented on DHR. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Barclays reduced their price target on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Citigroup reduced their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $277.00 price target (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Price Performance

Shares of DHR stock opened at $210.65 on Monday. The stock’s fifty day simple moving average is $225.79 and its 200 day simple moving average is $246.04. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a market cap of $150.56 billion, a price-to-earnings ratio of 39.90, a P/E/G ratio of 2.66 and a beta of 0.83. Danaher has a one year low of $196.80 and a one year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business earned $2.09 earnings per share.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.32 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DHR. Norges Bank bought a new position in shares of Danaher during the fourth quarter worth $2,130,740,000. FMR LLC boosted its position in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Danaher during the fourth quarter worth $391,172,000. Two Sigma Advisers LP boosted its position in shares of Danaher by 4,248.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock worth $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Finally, Capital World Investors boosted its position in shares of Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.